GlassScriptPhysician profile
Bruce S Solomon
NPI 1932165446
$4,486.03
in general payments reported to CMS, 2019-2025
36 companies · $150 in 2025
The $150 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,521 · 2020: $29.76 · 2021: $1,635 · 2023: $150 · 2025: $150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $300.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech, INC. | $1,485.00 | 2021 | |
| Biogen, INC. | $578.79 | 2019-2025 | Tysabri |
| Ucb, INC. | $376.81 | 2019 | |
| Genzyme Corporation | $230.60 | 2019 | |
| Mdd US Operations, LLC | $139.96 | 2019 | |
| Supernus Pharmaceuticals, INC. | $122.42 | 2019 | |
| Lundbeck LLC | $119.44 | 2019 | |
| Novartis Pharmaceuticals Corporation | $118.24 | 2019 | |
| Sunovion Pharmaceuticals INC. | $109.79 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $108.22 | 2019 | |
| Upsher-Smith Laboratories LLC | $84.51 | 2019 | |
| Lilly USA, LLC | $75.70 | 2019 | |
| Tanabe Pharma America, INC. | $73.05 | 2019 | |
| Bausch Health US, LLC | $67.00 | 2019 | |
| Eisai INC. | $60.98 | 2019 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $60.59 | 2019 | |
| Emd Serono, INC. | $59.61 | 2019 | |
| Allergan, INC. | $55.16 | 2019 | |
| Alexion Pharmaceuticals, INC. | $47.43 | 2019 | |
| Ge Healthcare | $46.99 | 2019 | |
| Csl Behring | $46.49 | 2019 | |
| Acorda Therapeutics, INC | $45.77 | 2019 | |
| Greenwich Biosciences, INC. | $37.89 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $36.27 | 2019 | |
| Acadia Pharmaceuticals INC | $33.28 | 2019 | |
| Mallinckrodt Enterprises LLC | $31.58 | 2019 | |
| Akcea Therapeutics, INC. | $30.65 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $29.76 | 2020 | |
| Adamas Pharmaceuticals, INC. | $27.61 | 2019 | |
| Grifols USA, LLC | $27.25 | 2019 | |
| Arbor Pharmaceuticals, INC. | $26.99 | 2019 | |
| Avanir Pharmaceuticals, INC. | $25.72 | 2019 | |
| Assertio Therapeutics, INC. | $23.18 | 2019 | |
| Philips North America LLC | $16.47 | 2019 | |
| Pfizer INC. | $15.87 | 2019 | |
| Promius Pharma LLC | $10.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Solomon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.